Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Next Previous
X
Search
Trial Profile

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seralutinib (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms TORREY OLE
  • Sponsors Gossamer Bio

    • Most Recent Events

    • 26 Aug 2024 According to a Gossamer Bio media release, company plans to present additional findings from this Phase 2 TORREY open-label extension study which highlight the sustained effect of seralutinib beyond 24 weeks of treatment, at the European Respiratory Society Conference 2024, which takes place from September 7th through 11th online and onsite in Vienna, Austria.
    • 22 May 2024 Interim results (data cut October 26, 2023) from this study evaluating long-term safety, tolerability, and efficacy of seralutinib in patients with PAH presented at the 120th International Conference of the American Thoracic Society.
    • 07 May 2024 According to Gossamer Bio media release, data from the ongoing TORREY Open Label Extension Study of seralutinib in patients with PAH will be featured at the American Thoracic Society (ATS) 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top